Drug Discovery

Anthropic’s breakthrough demonstrates the potential of frontier AI models to orchestrate complex scientific workflows spanning from in silico screening to wet-bench validation. For four decades, the vault particle remained an enigma, a massive protein complex found inside the cells of complex

The primary bottleneck in modern medicine is no longer the discovery of molecules but the ability to accurately predict which interventions will work for specific diseases. For decades, the pharmaceutical sector has operated under a paradigm that prioritized the synthesis of novel chemical

Artificial intelligence platforms such as AVIA and AutoHCS are currently demonstrating the ability to distinguish Zika virus-infected cells much earlier than traditional phenotypic profiling methods allowed. This breakthrough marks a definitive shift in the pharmaceutical industry, where the legacy

The landmark study published in The New England Journal of Medicine confirms that divarasib provides a statistically significant survival benefit that previous inhibitors failed to achieve. This clinical breakthrough addresses the specific challenges posed by the KRAS G12C mutation, which is

If clinical trials become validations of predictions rather than high-risk gambles, the type of capital available for early-stage research will likely undergo a significant shift. For decades, the pharmaceutical industry has operated under a cloud of uncertainty, where nearly half of all drug

Experimental data shows that these citrus-derived nanoparticles exhibit pH-responsive release, discharging eighty percent of their payload in acidic environments similar to tumor microenvironments. This precision delivery mechanism represents a significant leap forward in addressing the persistent